Cellular therapeutics are poised to be the next pillar of medicine along with small molecules and biologics. Advances in engineered T cell therapeutics are being FDA approved and are now transforming treatment plans for cancers that previously had few therapeutic options. While there have been unprecedented complete responses in a subset of hematological malignancies, the current therapies can show significant toxicity and on the other hand show a lack of efficacy in solid tumors. Beyond cancer, engineered cell therapies could have significant impact in the treatment of autoimmunity, metabolic disorders and in regenerative medicine.
This conference brings together clinically minded cell therapists, synthetic biologists, genome and protein engineers, systems biologists, and immunologists; this combined expertise is essential to establish cells as a safe and effective therapeutic strategy across a range of diseases. Smart cellular therapeutics of the future must be easily customizable, have intrinsic control systems to prevent toxicity, and be able to overcome rapidly evolving mechanisms preventing disease resolution; this conference aims to address these topics by convening global experts across a range of relevant disciplines.
Mogrify® has developed a proprietary suite of platforms that utilize a systematic big-data approach to direct cellular conversion (Rackham et al., Nature Genetics, 2016) and the maintenance of cell identity (Kamaraj et al., Cell Systems 2020). The platforms deploy next-generation sequencing, gene regulatory and epigenetic network data to enable the prediction of the transcription factors and culture medium conditions required to produce any target cell type from any source cell type.